# q09 rev 1 raw returns (tested_sha256 a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3)

Fresh agents dispatched 2026-10-06 by the caller (Claude Code, Opus 5.5) with only the workspace
root, their own packet path and the verbatim question (closed-book: question only). Returns are
copied verbatim from the task notifications.

## Blind solver A (blind-solver, packet solver-1)

**answer:** −2.6%

**confidence:** high

**path:**
1. **When FreeDM2 results were announced.** D08 (Q1 2026 release dated April 16, 2026), line 37: "In March, Abbott announced results from the FreeDM2 randomized controlled trial…". FreeDM2 appears nowhere else in the packet. A case-insensitive search for FreeDM, plus "basal insulin", "HbA1c", "fingerstick" and "randomized controlled", found only this line. So the announcement was in March 2026.
2. **Range in force in March 2026.** D07 (Jan. 22, 2026), lines 31 and 335: "Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint." The next change came in D08 on April 16, 2026. Its headline (line 15) reads "Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences", and lines 19/31/223 give "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences." No packet document between Jan. 22 and Apr. 16, 2026 changes the guidance. So the January range was in force in March, whatever the day.
3. **Range issued in July 2026.** D10 (July 16, 2026), line 29: "Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58." Line 329 confirms: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60." This confirms the order: January, then April, then July.
4. **Calculation.**
   - January midpoint = (5.55 + 5.80) / 2 = $5.675. As a check, 5.675 / 5.15 (FY2025 adjusted EPS in D07) = +10.2%, which matches "10 percent growth at the midpoint."
   - July midpoint = (5.45 + 5.60) / 2 = $5.525.
   - Change = (5.525 − 5.675) / 5.675 = −0.150 / 5.675 = −0.02643, or **−2.6%** to one decimal place.

**minimal_documents:** D07, D08, D10.
- D07 is the only source of the $5.55–$5.80 range.
- D08 is the only source dating FreeDM2 to March, and it shows the guidance was updated on April 16.
- D10 is the only source of the July range.

No substitutes exist in the packet. D01–D04 cover 2025 guidance. D05 is the Exact Sciences deal announcement, which only says the deal is "accretive to Abbott's revenue growth and gross margin" and gives no EPS guidance. D06 is the by-laws. D09 is a derivative-litigation settlement notice. D11 is the NEC litigation release.

**readings:**
- **Alternative (less defensible):** treat the range in force as the one in the April 16 release that reported the FreeDM2 announcement, $5.38–$5.58 (midpoint $5.48). Then (5.525 − 5.48) / 5.48 = +0.82%, or **+0.8%**. This conflicts with D08's own wording that the announcement happened "In March", before that release updated the guidance.
- Using rounded midpoints changes nothing: −2.6% under either rounding.

**gaps:**
- The exact day in March of the FreeDM2 announcement isn't given. This doesn't matter, because every March date falls between the Jan. 22 and Apr. 16 guidance releases.
- Exact Sciences closed on March 23, 2026 (D08). The packet has no mid-quarter guidance update at closing, and D08 says the update came on April 16. Any update outside the packet can't be ruled out.
- **Unread coverage:**
  - D07 and D10: read beyond the header and guidance sections only through search. The financial tables were not read.
  - D01–D04: read only through search hits (2025 guidance).
  - D05 and D06: read only their openings, plus searches for EPS, per-share, dilution and accretion terms. D06 had no hits; D05 had only the revenue/gross-margin accretion line.
  - D08, D09 and D11: read in full.
- No layout files or PDFs exist in this packet (all sources are .txt), so there was nothing extra to inspect.
- I did not read question.txt in the packet root, as instructed.

**contaminated:** no

Packet files used:
- D:\Dev\Docket\tasks\aq-00745\runs\q09-r1-v2-a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3\solver-1\text\D07.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q09-r1-v2-a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3\solver-1\text\D08.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q09-r1-v2-a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3\solver-1\text\D10.txt

## Blind solver B (blind-solver, packet solver-2)

**answer:** -2.6%

**confidence:** high

**path:**
1. **When the FreeDM2 results were announced.** FreeDM2 appears in only one document. D08, Abbott's Q1 2026 release dated April 16, 2026, line 37, says: "In March, Abbott announced results from the FreeDM2 randomized controlled trial…". So the announcement was in March 2026.
2. **The range in force in March 2026.** D07, dated Jan. 22, 2026, lines 17, 31 and 335, says: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". No later range appears until D08 (April 16, 2026). Its headline (line 15) reads "Updates Guidance to Reflect Acquisition of Exact Sciences", and lines 19, 31 and 223 give "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences".
   - The acquisition closed March 23, 2026 (D08 line 27). No document shows guidance changing when it closed. So whatever day in March the trial was announced, the January range was still in force.
3. **The July 2026 range.** D10, dated July 16, 2026, line 29, says: "Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58". Line 329 repeats the $5.45 to $5.60 range.
4. **Calculation:**
   - Midpoint in March: (5.55 + 5.80) / 2 = $5.675
   - Midpoint in July: (5.45 + 5.60) / 2 = $5.525
   - Change: (5.525 − 5.675) / 5.675 = −0.15 / 5.675 = −2.643%, which rounds to **−2.6%**
   - Check: 5.675 × 0.02643 = 0.14999.
5. **Cross-check against the originals.** The original files in docs/ contain the same strings: "$5.55 to $5.80" in abt_ex991_2026-01-22.txt, "$5.45 to $5.60" in abt_ex991_2026-07-16.txt, and "FreeDM2" and "Updates Guidance" in abt_ex991_2026-04-16.txt. These sources are text files, not PDFs, so there were no PDF pages to inspect.

**minimal_documents:** D07, D08, D10. None can be swapped out:
- D08 is the only document that mentions FreeDM2 and dates it.
- D07 is the only source of the $5.55–$5.80 range.
- D10 is the only source of the July range.

**readings:**
- **Using the April range instead.** One could read "range in force when it announced" as the range in the April 16 release that reports the trial (D08), which is also the "previous range" named in D10: $5.38–$5.58, midpoint $5.48. That gives (5.525 − 5.48) / 5.48 = +0.82%, or **+0.8%**. I reject this reading because D08 dates the announcement to March, before the April 16 update.
- **Dollar change.** The midpoint fell by $0.15.

**gaps:**
- No document gives the exact day in March of the FreeDM2 announcement. This doesn't affect the answer, because the next update came on April 16.
- **What I read:**
  - In full: D08, D09 (a court notice about the infant-formula shareholder derivative settlement) and D11 (the August 2026 settlement of preterm-formula NEC claims).
  - In part: D07 (lines 1–60 and 320–349), D10 (lines 1–60 and 318–337) and D06 (lines 1–25, which show it is Abbott's bylaws).
  - Searches only: D01–D05. I searched all of D01–D11 for FreeDM2 and its synonyms (HbA1c, basal insulin, randomized controlled, fingerstick, Type 2 diabetes), for guidance/outlook wording, and for the $5.38–$5.80 figures. Separate searches showed no "2026" EPS guidance in D01–D04, no guidance in D05 (the Exact Sciences deal announcement), and no "EPS" or "2026" in D06.
- I did not read the packet's question.txt.

**contaminated:** no

Files used, all under D:\Dev\Docket\tasks\aq-00745\runs\q09-r1-v2-a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3\solver-2\:
- text\D07.txt
- text\D08.txt
- text\D10.txt
- text\manifest.json

## Closed-book solver (question only, no tools used)

answer: unknown

confidence: low

basis: I recall with moderate confidence that in January 2026 Abbott guided full-year 2026 adjusted diluted EPS to $5.55–$5.80, a midpoint of $5.675. I can't remember when the FreeDM2 results were announced. That means I can't tell whether the range in force then was the January one or a later one, such as an April 2026 update that might have included the Exact Sciences acquisition. I also can't recall that April range. The range issued in July 2026 is after my June 2026 knowledge cutoff, so I can't calculate the percentage change. Any number I gave would be a guess.

contaminated: no

## Shortcut auditor (shortcut-auditor, packet shortcut)

answer: **-2.6%**. The midpoint fell from $5.675 to $5.525, so (5.525 - 5.675) / 5.675 = -0.15 / 5.675 = -2.643%, which rounds to -2.6%.

verdict: **clear**

shortest_path:
1. FreeDM2 appears in only one document, D08, the Q1 2026 release dated April 16, 2026, at line 37: "In March, Abbott announced results from the FreeDM2 randomized controlled trial…". It sits in the January/February/March list of quarter events, so this is March 2026.
2. Which range was in force in March 2026:
   - D07 (January 22, 2026), lines 31 and 335: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". The midpoint is $5.675.
   - That range was not replaced until D08 on April 16, 2026. D08's headline reads "…Updates Guidance to Reflect Acquisition of Exact Sciences", and lines 19 and 223 give "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences".
   - The acquisition closed on March 23, 2026 (D08 line 27), but the guidance only changed on April 16. So the January range was still in force throughout March.
3. July range: D10 (July 16, 2026), lines 29 and 329: "$5.45 to $5.60". The midpoint is $5.525.
4. The change is (5.525 - 5.675) / 5.675 = **-2.64%, or -2.6%**.

sufficient_documents: D07, D08 and D10 together; no smaller set works.
- D08 is the only document that dates FreeDM2, and it shows the April update came after March.
- D07 is the only document with the $5.55–$5.80 range.
- D10 is the only document with the July range.
- No single document contains both the March-era range and the July range.
- There is no alternative source, because no evidence is duplicated elsewhere.

searches:
- **Trial terms:** "FreeDM" and synonyms ("randomized", "HbA1c", "basal insulin", "fingerstick", "Type 2 diabetes", "glucose range"). These matched only D08:37.
- **Guidance terms:** "guidance", "outlook", "projects", "reaffirm", "diluted EPS", "earnings per share", "midpoint". Searched across D01–D11.
- **Guidance values:** "5.55", "5.80", "5.38", "5.58", "5.45", "5.60", plus possible midpoints "5.675", "5.48", "5.525". No document pre-computes a midpoint or percentage change for 2026.
- **"2026" in the 2025 documents:** no earlier 2026 EPS outlook exists. D05 (Exact Sciences deal announcement) only says closing is expected in Q2 2026.
- **Non-guidance documents:** D06 is the by-laws, D09 is a derivative-litigation settlement notice, and D11 is the August 2026 litigation settlement for preterm infant formula. None mentions guidance.
- **Read in full or in the relevant parts:** D07 header and guidance section, D08 lines 1–260, D10 header and guidance section, and the manifest.
- **Not read:** question.txt was deliberately not opened. Nothing leaked into this session.

readings/gaps:
- **Trap reading (+0.8%):** D10 compares the July range with "previous range of $5.38 to $5.58". Using that baseline gives (5.525 - 5.48) / 5.48 = +0.82%. But that range was issued on April 16, after the March FreeDM2 announcement, so it was not in force at the time.
- **Second reading (also +0.8%):** treating the April 16 release, which repeats the FreeDM2 news, as "when it announced results" leads to the same +0.8%. D08's wording ("In March, Abbott announced…") rules this out.
- **Approximation route (-2.7%):** rebuilding the January midpoint from D08's "$0.20 of dilution" (5.48 + 0.20 = 5.68) gives -2.7%. It is inexact and needs D10 anyway, so it is neither a valid shortcut nor a valid answer.
- **Like-for-like caveat:** the January range left out Exact Sciences, which had not closed yet, while the July range includes it. The question asks for the literal change in the midpoint, so this does not change the answer.
- **Difficulty risks:**
  - The answer depends on one date-matching step: March (D08) leads back to the January range (D07).
  - D10's built-in "previous range" comparison is the main trap.
  - The phrase "Give the sign" mildly hints that the sign matters, but it does not give away the value.
- **Gaps:**
  - The exact March day of the FreeDM2 announcement is not given. It does not matter, because no guidance change appears between January 22 and April 16.
  - The packet has no March 2026 filings. That there was no intervening update is inferred from D08's "Updates Guidance" headline and from D10's "previous range" chain.
  - D01–D06 were covered by targeted searches rather than read line by line.
  - The text files are direct text extractions, so there are no layout or OCR gaps.

Files:
- D:\Dev\Docket\tasks\aq-00745\runs\q09-r1-v2-a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3\shortcut\text\D07.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q09-r1-v2-a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3\shortcut\text\D08.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q09-r1-v2-a33b813ef2171a8c2fa5b0d20e599f2f2227feb3249c80ef3c61cd41c19bf0b3\shortcut\text\D10.txt
